(12) United States Patent
`Carter et al.
`
`111111
`
`1111111111111111111111111111111111111111111111111111111111111
`US006407213Bl
`US 6,407,213 Bl
`Jun.18,2002
`
`(10) Patent No.:
`(45) Date of Patent:
`
`........... C12P/21!08
`
`C12P/21!00
`
`C12P/21!08
`C12P/21!08
`
`.......... A61K/35/14
`
`0 592 106 A1
`0 620 276
`682040 A1
`451216 B1
`432249 B1
`2 188941
`wo 87/02671
`wo 88/09344
`wo 89/01783
`wo 89/06692
`wo 89/09622
`wo 90/07861
`90/07861
`wo 91!07492
`wo 91!07500
`wo 91/09966
`wo 91/09968
`wo 91/09967
`wo 92/01047
`wo 92/04380
`wo 92/04381
`wo 92/05274
`wo 92!11383
`wo 92!11018
`wo 92/15683
`wo 92/16562
`wo 92/22653
`wo 93/02191
`94!11509
`wo 94/12214
`OTHER PUBLICATIONS
`
`4/1994
`10/1994
`11/1995
`1!1996
`9/1996
`10/1987
`5/1987
`12/1988
`3/1989
`7/1989
`10/1989
`7/1990
`* 7/1990
`5/1991
`5/1991
`7/1991
`7/1991
`11/1991
`1!1992
`3/1992
`3/1992
`4/1992
`7/1992
`9/1992
`9/1992
`10/1992
`12/1992
`2/1993
`5/1994
`6/1994
`
`EP
`EP
`EP
`EP
`EP
`GB
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`wo
`
`(54) METHOD FOR MAKING HUMANIZED
`ANTIBODIES
`
`(75)
`
`Inventors: Paul J. Carter; Leonard G. Presta,
`both of San Francisco, CA (US)
`
`(73) Assignee: Genentech, Inc., South San Francisco,
`CA(US)
`
`( *) Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.:
`
`08/146,206
`
`(22) PCT Filed:
`
`Jun. 15, 1992
`
`(86) PCTNo.:
`
`PCT/US92/05126
`
`§ 371 (c)(l),
`(2), ( 4) Date: Nov. 17, 1993
`
`Related U.S. Application Data
`
`( 63) Continuation-in-part of application No. 07/715,272, filed on
`Jun. 14, 1991, now abandoned.
`
`Int. Cl? ................................................ C07K 16/00
`(51)
`(52) U.S. Cl. .................. 530/387.3; 435/69.6; 435/69.7;
`435/70.21; 435/91; 536/23.53; 424/133.1
`(58) Field of Search ............................... 435/69.6, 69.7,
`435/70.21, 91, 172.2, 240.1, 240.27, 252.3,
`320.1, 328; 536/23.53; 424/133.1; 530/387.3
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,816,567 A
`4,845,198 A
`5,132,405 A
`5,225,539 A
`5,530,101 A
`5,558,864 A
`5,585,089 A
`5,677,171 A
`5,693,762 A
`5,714,350 A
`5,772,997 A
`5,821,337 A
`5,834,598 A
`5,859,205 A
`
`3/1989 Cabilly et a!.
`7/1989 Urdal et a!.
`........... 530/388.22
`7/1992 Huston et a!.
`........... 530/387.3
`7/1993 Winter .................... 530/389.3
`6/1996 Queen et a!. . .. ... ... ... 530/387.3
`9/1996 Bendig et a!.
`........... 424/133.1
`12/1996 Queen et a!. . .. ... ... ... 424/133.1
`10/1997 Hudziak et a!.
`........... 435/7.23
`* 12/1997 Queen et a!. . .. ... ... ... 530/387.2
`................... 435/69.6
`2/1998 Co et a!.
`6/1998 Hudziak et a!.
`... ... ... 424/130.1
`10/1998 Carter et a!. .. .. ... ... ... 530/387.3
`11/1998 Lowman et a!. ............ 530/399
`1!1999 Adair et a!.
`.. .. ... ... ... 530/387.3
`
`FOREIGN PATENT DOCUMENTS
`
`........... C07K/15/12
`
`........... C12N/15/00
`
`......... A61K/39/395
`
`AU
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`
`85058/91
`120694
`125023 A1
`0 239 400
`323806 A1
`328404 A1
`338745 A1
`365209 A2
`365997 A2
`368684
`403156 A1
`438310 A2
`438312 A2
`440351 A2
`0 460 167 B1
`0 519 596 A1
`
`3/1992
`10/1984
`11/1984
`* 9/1987
`7/1989
`8/1989
`10/1989
`4/1990
`5/1990
`5/1990
`12/1990
`7/1991
`7/1991
`8/1991
`12/1991
`12/1992
`
`Riechmann et al. [Nature 332:323-327 (1988)].*
`Queen et al. [Proc. Natl. Acad. Sci. 86:10029-10033
`(1989)]. *
`Raitt [Immunology, published 1985, by Gower Medical
`Publishing Ltd. (London, England) p. 5 .5]. *
`Tramontano et al. [J. Mol. Biol. 215:175-182 (1990)].*
`"Biosym Technologies" in New Products, Chemical Design
`Automation 3 (Dec. 1988).
`"Polygen Corporation" in New Products, Chemical Design
`Automation 3 (Nov. 1988).
`Adair et al., "Humanization of the murine anti-human CD3
`monoclonal antibody OKT3" Hum. Antibod. Hybridomas
`5:41-47 (1994).
`Chothia et al., "Principles of protein-protein recognition"
`Nature 256:705-708 (1975).
`Chothia et al., "Transmission of conformational change in
`insulin" Nature 302:500-505 (1983).
`Corti et al., "Idiotope Determining Regions of a Mouse
`Monoclonal Antibody and Its Humanized Versions" J. Mol.
`Bioi. 235:53-60 (1994) .
`
`(List continued on next page.)
`
`Primary Examiner-Anthony C. Caputa
`Assistant Examiner -Minh-Tam Davis
`(74) Attorney, Agent, or Firm-Wendy M. Lee
`
`(57)
`
`ABSTRACT
`
`Variant immunoglobulins, particularly humanized antibody
`polypeptides are provided, along with methods for their
`preparation and use. Consensus immunoglobulin sequences
`and structural models are also provided.
`
`82 Claims, 9 Drawing Sheets
`
`BIOEPIS EX. 1001
`Page 1
`
`

`

`US 6,407,213 Bl
`Page 2
`
`01HER PUBLICATIONS
`
`Couto et al., "Anti-BA46 Monoclonal Antibody Mc3
`Humanization Using a Novel Positional Consensus and in
`Vivo and in Vitro Characterization" Cancer Research
`Supplement 55:1717-1722 (1995).
`Couto et al., "Humanization of KC4G3, an Anti-Human
`Carcinoma Antibody" Hybridoma 13:215-219 (1994).
`Ellis et al., "Engineered Anti-CD38 Monoclonal Antibodies
`for Immunotherapy of Multiple Myeloma" The Journal of
`Immunology pp. 925-937 (1995).
`Hieter et al., "Evolution of Human Immunoglobulin K J
`Region Genes" The Journal of Biological Chemistry
`257:1516-1522 (1982).
`Lesk, Arthur M., "How Different Amino Acid Sequences
`Determine Similar Protein Structures: The Structure and
`Evolutionary Dynamics of the Globins" J. Mol. Bioi.
`135:225-270 (1980).
`in T4
`Matsumura et al., "Hydrophobic stabilization
`lysozyme determined directly by multiple substitutions of
`Ile 3" Nature 334:406-410 (1988).
`Morrison, S. L., "Transfectomas Provide Novel Chimeric
`Antibodies" Science 229:1202-1207 (Sep. 20, 1985).
`Nakatani et al., "Humanization of mouse anti-human IL-2
`receptor antibody B-BlO" Protein Engineering 7:435-443
`(1994).
`Ohtomo et al., "Humanization of Mouse ONS-M21 Anti(cid:173)
`body with the Aid of Hybrid Variable Regions" Molecular
`Immunology 32:407-416 (1995).
`Rodrigues et al., "Engineering a humanized bispecific
`F(ab') 2 fragment for improved binding to T cells" Int. J.
`Cancer (Suppl.) 7:45-50 (1992).
`Sha et al., "A Heavy-Chain Grafted Antibody that Recog(cid:173)
`nizes the Tumor-Associated TAG72 Antigen" Cancer Rio(cid:173)
`therapy 9:341-349 (1994).
`Tempest et al., "Identification of framework residues
`required to restore antigen binding during reshaping of a
`monoclonal antibody against the glycoprotein gB of human
`cytomegalovirus" Int. J. Bioi. Macromol. 17:37-42 (1995).
`Tramontano, "Structural Determinants of the Conformations
`of Medium-Sized Loops in Proteins" Proteins 6:382-394
`(1989).
`Uchiyama et al., "A Monoclonal Antibody (Anti-Tac) Reac(cid:173)
`tive with Activated and Functionally Mature Human T
`Cells" Journal of Immunology 126:1393-1397 (1981).
`Vincenti et al., "Interleukin-2-Receptor Blockade with
`Daclizumab to Prevent Acute Rejection in Renal Transplan(cid:173)
`tation" New Engl. J. Med. 338:161-165 (1998).
`Vitetta et al., "Redesigning Nature's Poisons to Create
`Anti-Tumor Reagents" Science 238:1098-1104 (1987).
`Waldmann et al., "Interleukin 2 Receptor (Tac Antigen)
`Expression in HTLV -!-associated Adult T -Cell Leukemia"
`Cancer Research 45:4559s-4562s (1985).
`Waldmann, Thomas A., "The Structure, Function, and
`Expression of Interleukin-2 Receptors on Normal and
`Malignant Lymphocytes" Science 232:727-732 (1986).
`Wu et al., "An Analysis of the Sequences of the Variable
`Regions of Bence Jones Proteins and Myeloma Light Chains
`and Their Implications for Antibody Complementarity"
`Journal of Experimental Medicine 132:211-250 (1970).
`Rhodes, P., "Recombinant antibodies from CHO cells" Abstr
`Pap Am Chern Soc (Abstract No. 60 from the 199th Ameri(cid:173)
`can Chemical Society National Meeting held in Boston, MA
`Apr. 22-27, 1990) 199(1-2):BIOT 60 (Apr. 1990).
`
`Amzel and Poljak, "Three-dimensional structure of immu(cid:173)
`noglobulins" Ann. Rev. Biochem. 48:961-967 (1979).
`Bindon et al., "Human monoclonal IgG isotypes differ in
`complement activating function at the level of C4 as well as
`Clq" Journal of Experimental Medicine 168(1):127-142
`(Jul. 1988).
`Boulianne, G. L. et al., "Production of functional chimaeric
`mouse/human antibody" Nature 312(5995):643-646 (Dec.
`1984).
`Brown et al., "Anti-Tac-H, a humanized antibody to the
`interleukin 2 receptor, prolongs primate cardiac allograft
`survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991).
`Bruccoleri, "Structure of antibody hypervariable loops
`reproduced by a conformational search algorithm" Nature
`(erratum to article in Nature 335(6190):564--568 and)
`336:266 (1988).
`Bruggemann, M. et al., "Comparison of the effector func(cid:173)
`tions of human immunoglobulins using a matched set of
`chimeric antibodies" Journal of Experimental Medicine
`166:1351-1361 (1987).
`Burgess et al., "Possible Dissociation of the Heparin-bind(cid:173)
`ing and Mitogenic Activities of Heparin-binding (Acidic
`Fibroblast) Growth Factor-1 from Its Receptor-binding
`Activities by Site-directed Mutagenesis of a Single Lysine
`Residue" Journal of Cell Biology 111:2129-2138 (1990).
`Carter et al., "Humanization of an anti-p185HER2 antibody
`therapy" Proc. Natl. Acad. Sci.
`for human cancer
`89:4285-4289 (1992).
`Cheetham, J., "Reshaping the antibody combining site by
`CDR replacement-tailoting or tinkering to fit?" Protein
`Engineering 2(3):170--172 (1988).
`Chothia and Lesk, "Canonical Structures for the Hypervari(cid:173)
`able Regions" J. Mol. Bioi. 196:901-917 (1987).
`Chothia et al., "The predicted structure of immunoglobulin
`D1.3 and its comparison with the crystal structure" Science
`233:755-758 (Aug. 15, 1986).
`Chothia, C. et al., "Conformations of immunoglobulin
`hypervariable regions" Nature 342(6252):877-883 (1989).
`Chothia, Cyrus, "Domain association in immunoglobulin
`molecules: The packing of variable domains" J. Mol. Bioi.
`186:651-663 (1985).
`Clark et al., "The improved lytic function and in vivo
`efficacy of monovalent monoclonal CD3 antibodies" Euro(cid:173)
`pean Journal of Immunology 19:381-388 (1989).
`Co et al., "Humanized antibodies for antiviral therapy" Proc.
`Natl. Acad. Sci. USA 88:2869-2873 (1991).
`Coussens et al., "Tyrosine Kinase Receptor with Extensive
`Homology to EGF Receptor Shares Chromosomal Location
`with neu Oncogene" Science 230:1132-1139 (1985).
`Daugherty, BL et al., "Polymerase chain reaction facilitates
`the cloning, CDR-grafting, and rapid expression of a murine
`monoclonal antibody directed against the CD18 component
`integrins" Nucleic Acids Research
`of
`leukocyte
`19(9):2471-2476 (May 11, 1991).
`Davies, D. R. et al., "Antibody-Antigen Complexes" Ann.
`Rev. Biochem. 59:439-473 (1990).
`Epp et al., "The molecular structure of a dimer composed of
`the variable portions of the Bence-Janes protein REI refined
`resolution" Biochemistry 14(22):4943-4952
`at 2.0--A
`(1975).
`Fendly et al., "Characterization of murine monoclonal anti(cid:173)
`bodies reactive to either the human epidermal growth factor
`receptor or HER2/neu gene product" Cancer Research
`50:1550-1558 (1990).
`
`BIOEPIS EX. 1001
`Page 2
`
`

`

`US 6,407,213 Bl
`Page 3
`
`Furey et al., "Structure of a novel Bence-Janes protein
`(Rhe) fragment at 1.6 A resolution" J. Mol. Bioi.
`167(3):661-692 (Jul. 5, 1983).
`Gorman, SD et al., "Reshaping a therapeutic CD4 antibody"
`Proc. Natl. Acad. Sci. USA 88(10):4181-4185 (May 15,
`1991).
`Gregory et al., "The solution conformations of the sub(cid:173)
`classes of human IgG deduced from sedimentation and small
`angle X-ray scattering studies" Molecular Immunology
`24(8):821-829 (Aug. 1987).
`Hale et al., "Remission induction in non-hodgkin lym(cid:173)
`phoma with
`reshaped human monoclonal antibody
`campath-1H" Lancet 1:1394-1399 (1988).
`Harris and Emery, "Therapeutic antibodies-the coming of
`age" Tibtech 11:42-44 (Feb. 1993).
`Huber et al., "Crystallographic structure studies of an IgG
`molecule and an Fe fragment" Nature 264:415-420 (Dec. 2,
`1976).
`Hudziak et al., "p185HER2 Monoclonal Antibody Has Anti(cid:173)
`proliferative Effects In Vitro and Sensitizes Human Breast
`Tumor Cells to Tumor Necrosis Factor" Molecular & Cel(cid:173)
`lular Biology 9(3):1165-1172 (1989).
`Jaffers, G. J. et al., "Monoclonal antibody therapy. Anti-id(cid:173)
`iotypic and non-anti-idiotypic antibodies to OKT3 arising
`despite
`intense
`immunosuppression" Transplantation
`41(5):572-578 (May 1986).
`Jones, P. T. et al., "Replacing the complementarity-deter(cid:173)
`mining regions in a human antibody with those from a
`mouse" Nature 321(6069):522-525 (1986).
`Junghans et al., "Anti-Tac-H, a humanized antibody to the
`interleukin 2 receptor with new features for immunotherapy
`in malignant and immune disorders" Cancer Research
`50(5):1495-1502 (Mar. 1, 1990).
`Kabat et al. Sequences of Proteins of Immunological Inter(cid:173)
`est, Bethesda, MD:National Institutes of Health pp. iii-xx(cid:173)
`vii, 41-176 (1987).
`King et al., "Amplification of a Novel v--erbB-Related Gene
`in a Human Mammary Carcinoma" Science 229:974--976
`(1985).
`Lazar et al., "Transforming Growth Factor a: Mutation of
`Aspartic Acid 47 and Leucine 48 Results in Different
`Biological Activities" Molecular & Cellular Biology
`8(3):1247-1252 (1988).
`Love et al, "Recombinant antibodies possessing novel effec(cid:173)
`tor functions" Methods in Enzymology 178:515-527 (1989).
`Lupu et al., "Direct interaction of a ligand for the erbB2
`oncogene product with the EGF receptor and p185erbB2
`"
`Science 249:1552-1555 (1990).
`Margni RA and Binaghi RA, "Nonprecipitating asymmetric
`antibodies" Ann. Rev. Immunol. 6:535-554 (1988).
`Margolies et al., "Diversity of light chain variable region
`sequences among rabbit antibodies elicited by the same
`antigens." Proc. Natl. Acad. Sci. USA 72:2180--84 (Jun.
`1975).
`Marquart et al., "Crystallographic refinement and atomic
`models of the intact immunoglobulin molecule Kol and its
`antigen-binding fragment at 3.0 A and 1.0 A resolution" J.
`Mol. Bioi. 141(4):369-391 (Aug. 25, 1980).
`Mian, IS et al., "Structure, function and properties of anti(cid:173)
`body binding sites" J. Mol. Bioi. 217(1):133-151 (Jan. 5,
`1991).
`Miller, R. et al., "Monoclonal antibody therapeutic trials in
`seven patients with T -cell lymphoma" Blood 62:988-995
`(1983).
`
`Morrison, S. L. et al., "Chimeric human antibody molecules:
`mouse antigen-binding domains with human constant
`region
`domains" Proc. Natl. Acad.
`Sci. USA
`81(21):6851-6855 (Nov. 1984).
`Neuberger et al., "Recombinant antibodies possessing novel
`effector functions" Nature 312(5995):604-608 (Dec. 1984).
`Neuberger, M. S. et al., "A hapten-specific chimaeric IgE
`antibody with human physiological effector function"
`Nature 314(6008):268-270 (Mar. 1985).
`Novotny and Haber, "Structural invariants of antigen bind(cid:173)
`ing: comparison of immunoglobulin VL-V H and VL-VL
`domain
`dimers" Proc. Natl. Acad.
`Sci. USA
`82(14):4592-4596 (Jul. 1985).
`Pluckthun, Andreas, "Antibody engineering: advances from
`the use of Escherichia coli expression systems" Biotechnol(cid:173)
`ogy 9:545-51 (1991).
`Queen, M. et al., "A humanized antibody that binds to the
`interleukin 2 receptor" Proc. Natl. Acad. Sci. USA
`86:10029-10033 (1989).
`Riechmann, L. et al., "Reshaping human antibodies for
`therapy" Nature 332:323-327 (1988).
`Raitt et al. Immunology (Gower Medical Publishing Ltd.,
`London, England) pp. 5.5 (1985).
`Saul et al., "Preliminary refinement and structural analysis
`of the Fab fragment from human immunoglobulin new at 2.0
`A
`resolution"
`Journal
`of Biological Chemistry
`253(2):585-597 (Jan. 25, 1978).
`Schroff, R. et al., "Human anti-murine immunoglobulin
`responses
`in patients receiving monoclonal antibody
`therapy" Cancer Research 45:879-885 (1985).
`Segal et al., "The three-dimensional structure of a phospho(cid:173)
`rylcholine-binding mouse immunoglobulin Fab and the
`nature of the antigen binding site" Proc. Natl. Acad. Sci.
`USA 71(11):4298-4302 (Nov. 1974).
`Shalaby et al., "Development of humanized bispecific anti(cid:173)
`bodies reactive with cytotoxic lymphocytes and tumor cells
`overexpressing
`the HER2 protooncogene" Journal of
`Experimental Medicine 175(1):217-225 (Jan. 1, 1992).
`Shepard and Lewis, "Resistance of tumor cells to tumor
`necrosis factor" J. Clin. Immunol. 8(5):333-395 (1988).
`Sheriff et al., "Three-dimensional structure of an antibody(cid:173)
`antigen
`complex" Proc. Natl. Acad.
`Sci. USA
`84(22):8075-8079 (Nov. 1987).
`Sherman et al., "Haloperidol binding to monoclonal anti(cid:173)
`bodies" Journal of Biological Chemistry 263:4064-4074
`(1988).
`Silverton et al., "Three-dimensional structure of an intact
`human immunoglobulin" Proc. Natl. Acad. Sci. USA
`74:5140-5144 (1977).
`Slamon et al., "Human Breast Cancer: Correlation of
`Relapse and Survival with Amplification of the HER-2/neu
`Oncogene" Science 235:177-182 (1987).
`Slamon et al., "Studies of the HER-2/neu proto-oncogene in
`human breast and ovarian cancer" Science 244:707-712
`(1989).
`Snow and Amzel, "Calculating three-dimensional changes
`in protein structure due to amino-acid substitutions: the
`variable region of immunoglobulins" Protein: Structure,
`Function, and Genetics, Alan R. Liss, Inc. vol. 1:267-279
`(1986).
`Sox et al., "Attachment of carbohydrate to the variable
`region of myeloma immunoglubulin light chains" Proc.
`Natl. Acad. Sci. USA 66:975-82 (Jul. 1970).
`
`BIOEPIS EX. 1001
`Page 3
`
`

`

`US 6,407,213 Bl
`Page 4
`
`Spiegelberg et al., "Localization of the carbohydrate within
`the variable region of light and heavy chains of human yG
`myeloma proteins" Biochemistry 9:4217-23 (Oct. 1970).
`Takeda et al., "Construction of chimaeric processed immu(cid:173)
`noglobulin genes containing mouse variable and human
`constant region sequences" Nature 314(6010):452-454
`(Apr. 1985).
`Tao et al., "Role of Carbohydrate in the Structure and
`Effector Functions Mediated by the H uman IgG Constant
`Region" J. Immunol. 143(8):2595-2601 (1989).
`Tramontano et al., "Framework residue 71 is a major deter(cid:173)
`minant of the position and conformation of the second
`hypervariable region in the VH domains of immunoglobu(cid:173)
`lins" J-Mol-Bio/215(1):175-182 (Sep. 5, 1990).
`Verhoeyen, M. et al., "Reshaping human antibodies: grafting
`an antilysozyme activity" Science 239( 4847): 1534-1536
`(Mar. 25, 1988).
`Waldmann, T., "Monoclonal antibodies in diagnosis and
`therapy" Science 252:1657-1662 (1991).
`Wallick et al., "Glycosylation of a VH residue of a mono(cid:173)
`clonal antibody against alpha (1--6) dextran increases its
`affinity for antigen" Journal of Experimental Medicine
`168(3):1099-1109 (Sep. 1988).
`Winter and Milstein, "Man-made antibodies" Nature
`349(6307):293-299 (Jan. 24, 1991).
`Yamamoto et al., "Similarity of protein encoded by the
`human c-erb-B-2 gene to epidermal growth factor recep(cid:173)
`tor" Nature 319:230--34 (1986).
`Carter et al., "High level escherichia coli expression and
`production of a bivalent humanized antibody fragment"
`Bio/Technology 10:163-167 (1992).
`Foote et al., "Antibody Framework Residues Affecting the
`Conformation of the Hypervariable Loops" J. Mol. Bioi.
`224:487-499 (1992).
`Foote, J., "Humanized Antibodies" Nova acta Leopoldina
`61(269):103-110 (1989).
`Kabat et al., "Sequences of Proteins of Immunological
`Interest", Bethesda, MD:National Institute of Health pp.
`14-32 (1983).
`Kettleborough et al., "Humanization of a Mouse Mono(cid:173)
`clonal Antibody by CDR-grafting:
`the Importance of
`Framework Residues on Loop Conformation" Protein Engi(cid:173)
`neering 4(7):773-783 (1991).
`Maeda et al., "Construction of Reshaped Human Antibodies
`with HIV-neutralizing Activity" Hum. Antibod. Hybrido(cid:173)
`mas 2:124-134 (Jul. 1991).
`Riechmann et al, "Expression of an Antibody Fv Fragment
`in Myeloma Cells" J. Mol. Bioi. 203:825-828 (1988).
`Routledge et al., "A Humanized Monovalent CD3 Antibody
`which Can Activate Homologous Complement" European
`Journal of Immunology 21:2717-2725 (1991).
`Shearman et al., "Construction, Expression and Character(cid:173)
`ization of Humanized Antibodies Directed Against the
`Human
`a/~ T Cell Receptor"
`J.
`Immunol.
`147(12):4366-4373 (Dec. 15, 1991).
`Tempest et al., "Reshaping a Human Monoclonal Antibody
`to Inhibit Human Respiratory Syncytial Virus Infection In
`Vivo" Bio/Technology 9:266-271 (Mar. 1991).
`Brown, Jr. et al., "Anti-Tac-H, a humanized antibody to the
`interleukin 2 receptor, prolongs primate cardiac allograft
`survival" Proc. Natl. Acad. Sci. USA 88:2663-2667 (1991).
`Casale et al., "Use of an anti-IgE humanized monoclonal
`antibody in ragweed-induced allergic rhinitis" J. Allergy
`Clin. Immunol. 100:110--121 (1997).
`
`Fahy et al., "The Effect of an Anti-IgE Monoclonal Anti(cid:173)
`body on the Early- and Late-Phase Responses to Allergen
`Inhalation in Asthmatic Subjects" Am J. Respir. Crit. Care
`Med 155:1828-1834 (1997).
`Mathieson et al., "Monoclonal-Antibody Therapy in Sys(cid:173)
`temic Vasculitis" New England J. of Medicine pp. 250--254
`(Jul. 1990).
`Presta et al., "Humanization of an anti-vascular endothelial
`growth factor monoclonal antibody for the therapy of solid
`tumors
`and
`other
`disorders" Cancer Research
`57(20):4593-4599 (Oct. 15, 1997).
`Amit et al., "Three-Dimensional Structure of an Anti(cid:173)
`gen-Antibody Complex at 2.8 A Resolution" Science
`233:747-753 (Aug. 1986).
`Amzel et al., "The Three Dimensional Structure of a Com(cid:173)
`bining Region-Ligand Complex of Immunglobulin New at
`3.5-A Resolution" Proc. Natl. Acad.
`Sci. USA
`71(4):1427-1430 (Apr. 1974).
`Baselga et al., "Phase II Study of Weekly Intravenous
`Recombinant Humanized Anti-p185/HER2 Monoclonal
`Antibody
`in Patients With HER2/neu-Overexpressing
`Metastatic Breast Cancer" J. Clin. Oneal. 14(3):737-744
`(1996).
`Beverley & Callard, "Distinctive functional charcteristics of
`human "T" lymphocytes defined by E rosetting or a mono(cid:173)
`clonal anti-T cell antibody" European Journal of Immunol(cid:173)
`ogy 11:329-334 (1981).
`Bird et al., "Single-chain antigen-binding proteins" Science
`242:423-426 (Oct. 1988).
`Brennan et al., "Preparation of bispecific antibodies by
`chemical recombination of monoclonal immunoglobulin G1
`fragments" Science 229:81-83 (Jul. 1985).
`Bruccoleri et al., "Structure of antibody hypervariable loops
`reproduced by a conformational search algorithm" Nature
`335:564-568 (Oct. 1988).
`Caron et al., "Biological and Immunological Features of
`Humanized M195 (Anti-CD33) Monoclonal Antibodies"
`Cancer Research 52:6761-6767 (Dec. 1992).
`Chothia & Lesk, "The relation between the divergence of
`sequence and structure
`in proteins" EMBO Journal
`5( 4):823-826 (1986).
`Co & Queen, "Humanized antibodies for therapy" Nature
`351:501-502 (Jun. 1991).
`Co et al., "Chimeric and Humanized Antibodies with Speci(cid:173)
`ficity
`for
`the CD33 Antigen" J. of Immunology
`148(4):1149-1154 (Feb. 1992).
`Co et al., "Humanized Anti-Lewis Y Antibodies: In Vitro
`Properties and Pharmacokinetics in Rhesus Monkeys" Can(cid:173)
`cer Research 56:1118-1125 (Mar. 1996).
`Colman et al., "Crystal and Molecular Structure of the
`Dimer of Variable Domains of the Bence-Janes Protein
`ROY" J. Mol. Bioi. 116:73-79 (1977).
`Colman et al., "Three-dimensional structure of a complex of
`antibody with
`influenza virus neuraminidase" Nature
`326:358-363 (Mar. 1987).
`Cook et al., "A map of the human immunoglbulin V H locus
`completed by analysis of the telometric region of chromo(cid:173)
`some 14q" Nature Genetics 7:162-168 (Jun. 1994).
`five
`"Nucleotide
`sequences of
`Darsley & Rees,
`anti-lysozyme monoclonal antibodies" EMBO Journal
`4(2):393-398 (1985).
`Davies & Metzger, "Structural Basis of Antibody Function"
`Ann. Rev. Immunol. 1:87-117 (1983).
`
`BIOEPIS EX. 1001
`Page 4
`
`

`

`US 6,407,213 Bl
`Page 5
`
`Davies et al., "Antibody-Antigen Complexes" Journal of
`Biological Chemistry 263(22): 10541-10544 (Aug. 1988).
`Eigenbrot et al., "X-Ray Structures of Fragments From
`Binding and Nonbinding Versions of a Humanized
`Anti-CD18 Antibody: Structural Indications of the Key
`Role of V H Residues 59 to 65" Proteins 18:49-62 (1994).
`Eigenbrot et al., "X-ray structures of the antigen-binding
`domains from three variants of humanized anti-p185HER2
`antibody 4D5 and comparison with molecular modeling" J.
`Mol. Bioi. 229:969-995 (1993).
`Ellison et al., "The nucleotide sequence of a human immu(cid:173)
`noglobulin
`gene" Nucleic Acids Research
`Cy1
`10(13):4071-4079 (1982).
`Emery & Adair, "Humanised monoclonal antibodies for
`therapeutic applications" Exp. Opin.
`Invest. Drugs
`3(3):241-251 (1994).
`Epp et al., "Crystal and Molecular Structure of a Dimer
`Composed of the Variable Portions of the Bence-Janes
`Protein REI" European Journal of Biochemistry 45:513-524
`(1974).
`Fanger et al., "Bispecific antibodies and targeted cellular
`cytotoxicity" Immunology Today 12(2):51-54 (1991).
`Fanger et al., "Cytotoxicity mediated by human Fe receptors
`for IgG" Immunology Today 10(3):92-99 (1989).
`Feldmann et al., "A Hypothetical Space-Filling Model of
`the V-Regions of the Galactan-Binding Myeloma Immu(cid:173)
`noglobulin J539" Molecular Immunology 18(8):683-698
`(1981).
`Fendley et al., "The Extracellular Domain of HER2/neu Is a
`Potential Immunogen for Active Specific Immunotherapy of
`Breast Cancer" J. Bioi. Resp. Mod. 9:449-455 (1990).
`Glennie et al., "Preparation and Performance of Bispecific
`F(ab'y)2 Antibody Containing Thioether-Linked Fab'y Frag(cid:173)
`ments" J. Immunol. 139(7):2367-2375 (Oct. 1, 1987).
`Gonzalez et al., "Humanization of Murine 6G425:An
`Anti-IL8 Monoclonal Antibody Which Blocks Binding of
`IL8 to Human Neutrophils" 1996 Keystone Symposia on
`Exploring and Exploiting Antibody and Ig Superfamily
`Combining Sites (Poster) pp. 1-21 (Feb. 1996).
`Gussow & Seemann, "Humanization of Monoclonal Anti(cid:173)
`bodies" Meth. Enzymology, Academic Press, Inc. vol.
`203:99-121 (1991).
`Hieter et al., "Cloned human and mouse kappa immunoglo(cid:173)
`bulin constant and J region genes conserve homology in
`functional segments" Cell 22 (Part 1):197-207 (1980).
`Houghton, A, "Building a better monoclonal antibody"
`Immunology Today 9(9):265-267 (1988).
`Huston et al., "Protein engineering of antibody binding sites:
`Recovery of specific activity in an anti-digoxin single-chain
`Fv analogue produced in Escherichia coli" Proc. Natl.
`Acad. Sci. USA 85:5879-5883 (Aug. 1988).
`Isaacs et al., "Humanised Monoclonal Antibody Therapy for
`Rheumatoid Arthritis" Lancet 340:748-752 (Sep. 26, 1992).
`Johnson et al., "Biological and Molecular Modeling Studies
`Comparing Murine Monoclonal Antibodies with Their Engi(cid:173)
`neered Chimeric and Humanized Counterparts" J. Cell.
`Biochem. Suppl 0 (13 Part A) (18th Ann. UCLA Symp on
`Mol. & Cell. Biol., Park City, UT Jan. 17-22, 1989) pp. 87
`(1989).
`Kabat E., "Origins of Antibody Complementarity and Speci(cid:173)
`ficity-Hypervariable Regions and the Minigenen Hypoth(cid:173)
`esis" J. of Immunology 125(3):961-969 (Sep. 1980).
`
`Kabat et al. Sequences of Proteins of Immunological Inter(cid:173)
`est, U.S. Dept. of Health and Human Services, NIH, 5th
`edition vol. 1:103-108, 324-331 (1991).
`Kindt & Capra The Antibody Enigma, New York:Plenum
`Press pp. 79-86 (1984).
`Lesk & Chothia, "Evolution of Proteins Formed by
`~-Sheets" J. Mol. Bioi. 160:325-342 (1982).
`Lesk & Chothia, "The response of protein structures to
`amino-acid sequence changes" Phil. Trans. R. Soc. Land. A
`317:345-356 (1986).
`Mariuzza et al., "The Structure Basis of Antigen-Antibody
`Recognition" Ann. Rev. Biophys. Biophys. Chern.
`16:139-159 (1987).
`Nadler et al., "Immunogenicity of Humanized and Human
`Monoclonal Antibodies" Clin. Pharmacology & Therapeu(cid:173)
`tics pp. 180 (Feb. 1994).
`Nelson, H., "Targeted Cellular Immunotherapy with Bifunc(cid:173)
`tional Antibodies" Cancer Cells 3:163-172 (1991).
`Neuberger et al., "Antibody Engineering" Proceedings 8th
`Inti. Biotech. Symp., Paris 11:792-799 (1988).
`Newmark, P., "Making Chimeric Antibodies Even More
`Human" Bio/Technology 6:468 (May 1988).
`Nishimura et al., "Human c-erbB-2 Proto-Oncogene Prod(cid:173)
`uct as a Target for Bispecific-Antibody-Directed Adoptive
`Tumor Immunotherapy" Int. J. Cancer 50:800-804 (1992).
`Nitta et al., "Preliminary trial of specific targeting therapy
`against malignant glioma" Lancet 335(8686):368-371 (Feb.
`17, 1990).
`Nitta, T. et al., "Bispecific F(ab')2 monomer prepared with
`anti-CD3 and anti-tumor monoclonal antibodies is most
`potent in induction of cytolysis of human T cells" European
`Journal of Immunology 19:1437-1441 (1989).
`Nolan et al., "Bifunctional antibodies: concept, production
`and applications" Biochimica et Biophysic a Acta 1040:1-11
`(1990).
`O'Connor et al., "Calcium Dependence of an Anti-Protein C
`Humanized Antibody
`Involves Framework Residues"
`(manuscript).
`Orlandi et al., "Cloning Immunoglobulin Variable Domains
`for Expression by the Polymerase Chain Reaction" Proc.
`Natl. Acad. Sci. USA 86:3833-3837 (May 1989).
`Orlandi et al., "Cloning of eDNA Corresponding to Heavy
`and Light Chain Immunoglobulin Variable Domains" Pro(cid:173)
`tein and Pharmaceutical Engineering pp. 90 (1989).
`Ostberg & Queen, "Human and humanized monoclonal
`antibodies: preclinical studies and clinical experience" Bio(cid:173)
`chem. Soc. Transactions pp. 1038-1043 (1995).
`Pedlan et al., "Model-building Studies of Antigen-binding
`Sites:The Hapten-binding Site of MOPC-315" Cold
`Springs Harbor Symposia On Quantitative Biology
`XLI:627-637 (1977).
`Padlan, E., "Anatomy of the Antibody Molecule" Molecular
`Immunology 31(3):169-217 (1994).
`Padlan, E., "Evaluation of the Structural Variation Among
`Light Chain Variable Domains" Molecular Immunology
`16:287-296 (1979).
`Palm & Hilschmann, "Primary structure of a crystalline
`monoclonal immunoglobulin K-type L-chain, subgroup I
`(Bence-Janes preotin Rei); isolation & characterization of
`the tryptic peptides: ... " Hoppes-Seyler's Z. Physiol.
`Chern. 356:167-191 (Feb. 1975).
`
`BIOEPIS EX. 1001
`Page 5
`
`

`

`US 6,407,213 Bl
`Page 6
`
`Palm & Hilschmann, "The primary structure of a crystalline,
`monoclonal immunoglobulin-L-chain of the x-type, sub(cid:173)
`group I (Bence-Janes Protein Rei): a contribution to the
`elucidation of the three-dimensional structure of the immu(cid:173)
`noglobulins" Hoppe-Seyler's
`Z.
`Physiol.
`Chern.
`354:1651-1654 (Dec. 1973).
`Panka et al., "Variable region framework differences result
`in decreased or increased affinity of variant anti-digoxin
`antibodies" Proc. Natl. Acad. Sci. USA 85:3080-3084 (May
`1988).
`Presta et al., "Humanization of an Antibody Directed
`Against IgE" J. Immunol. 151(5):2623-2632 (Sep. 1, 1993).
`Preval & Fougereau, "Specific Interaction between V Hand
`VL Regions of Human Monoclonal Immunoglobulins" J.
`Mol. Bioi. 102:657-678 (1976).
`Queen et al., "Construction of Humanized Antibodies and
`Testing in Primates" J. Cell. Biochem. Suppl. 15 (Part E)
`(20th Ann. Mtg. Keystone Symp. Denver, CO Mar. 10-16,
`1991) pp. 137 (1991).
`Queen et al., "Humanised antibodies to the IL-2 receptor"
`Protein Eng. Antibody Mol. Prophyl. Ther. Appl. Man,
`Clark, M., Nottingham, UK:Academic Titles pp. 159-170
`(1993).
`Rhodes & Birch, "Large-Scale Production of Proteins from
`Mammalian Cells" Rio/Technology 6:518, 521, 523 (May
`1988).
`Riechmann, "Humanizing of Recombinant Antibodies"
`(Intl. Symp. on Clin. Appl. of Monoclonal Antibodies,
`Guildford, England) pp. 33-34 (Sep. 1987).
`Riechmann & Winter, "Recombinant Antibodies" (U. of
`London Royal Postgraduate Medical School, Wolfson Insti(cid:173)
`tute, Abstract) (May 1987).
`Riechmann et al. Alignment of VL Sequences (1988).
`Roberts & Rees, "Generation of an antibody with enhanced
`affinity and specificity for its antigen by protein engineer(cid:173)
`ing" Nature 328:731-734 (Aug. 1987).
`Rostapshov et al., "Effective method for obtaining long
`nucleotide chains on partially complementary templates"
`FEES Letters 249(2):379-382 (Jun. 1989).
`Schneider et al., "The Anti-Idiotypic Response by Cyno(cid:173)
`molgus Mondkeys to Humanized Anti-Tac Is Primarily
`Directed to Complementarity-Determining Regions Hl, H2,
`and L3" J. of Immunology 150:3086-3090 (Apr. 1993).
`Sedlacek et al., "Monoclonal Antibodies
`in Tumor
`Therapy", Karger pp. 119-126, 133-179 (1988).
`Shields et al., "Inhibition of Allergic Reactions with Anti(cid:173)
`bodies to IgE" International Archives of Allergy and Immu(cid:173)
`nology 107(1-3):308-312 (May 1995).
`Sims et al., "A Humanized CD18 Antibody Can Block
`Function Without Cell Destruction" The Journal of Immu(cid:173)
`nology 151(4):2296-2308 (Aug. 1993).
`Smith-Gill et al., "A Three